Psoriasis is a systemic, chronic, immunologically mediated disease, with significant genetic and environmental influences. It affects from 1 to 3% of the world population. Recently, the relation between psoriasis and different comorbidities, particularly metabolic syndrome, has become extremely relevant. Uveitis is characterized by a process of intraocular inflammation resulting from various causes. Considering psoriasis and uveitis as immune-mediated diseases, this study aims to evaluate the possible association of psoriasis and/or psoriatic arthritis with uveitis and its subtypes. Few studies have evaluated the association of uveitis and psoriasis without joint involvement. It seems that psoriasis without arthropathy is not a risk factor for the development of uveitis. Uveitis tends to develop more frequently in patients with arthropathy or pustular psoriasis than in patients with other forms of psoriasis. Ophthalmic examination should be performed periodically in patients with psoriasis and uveitis. If ophthalmopathy is diagnosed, the patient should receive adequate treatment with anti-inflammatory drugs or immunomodulators to prevent vision loss.

Psoriasis affects 0.12% to 0.71% of all chil dren. Erythrodermic pso ria sis is an uncom mon but serious disor der, occur ring in less than 1.5% of cases. Tumor necro sis fac tor-alpha bloc kers (TNF-α) are a new class of drugs used to treat mode ra te to seve re pso ria sis refrac tory to con ven tio nal the ra pies. Etanercept is a TNFα recep tor fusion pro tein, appro ved by the FDA for trea ting juve ni le rheu ma toid arth ri tis. We pre sent the case of a 7-year-old suf fe ring from pla que pso ria sis since 8 months old which evol ved into eryth ro der ma refrac tory to cyclos po ri ne and metho tre xa te. Patient res pon ded excel lently to eta ner cept, with no adver se side effects. Keywords: Child; Psoriasis; Therapy Resumo: A pso ría se aco me te 0,12% a 0,71% da popu la ção infan til, sendo que a forma eri tro dér mi ca, grave e rara, ocor re em menos de 1,5% dos casos. Os anta go nis tas do Fator de Necrose Tumoral-α (TNF-α) cons ti tuem nova clas se de dro gas, uti li za da para tra ta men to da pso ría se grave a mode ra da, refra tá ria às tera pias con ven cio nais. O Etanercepte é uma pro teí na de fusão do recep tor do TNF-α, apro va da pelo Food and Drug Administration para tra ta men to da artri te reu ma toi de juve nil no grupo infan til. Apresentamos um caso de crian ça com 7 anos de idade, com pso ría se em placa desde 8 meses de vida, que evo luiu para eri tro der mia refra tá ria a ciclos po ri na e meto tre xa to, com exce len te res pos ta ao eta nercep te, sem fei tos adver sos. Palavras-chave: Criança; Psoríase; Terapêutica ©2011 by Anais Brasileiros de Dermatologia CASE REPORT INTRODUCTIONPsoriasis is a chronic systemic inflammatory disorder which affects 1-3% of the world´s population. A population-based study 1 reveals that the annual incidence of childhood psoriasis is 33.2 cases per 100,000 children. Child psoriasis affects 0.71% of the population under 18 and its prevalence increases linearly with age, from 0.12% in 1 year-olds to 1.2% in 18 yearolds. It is estimated that the disease begins before children reach 16 in 25-45% of cases and before age 2 in 2% of patients.